FdaApplication
NDA 020387
Identifiers
- fda_app_no: NDA020387
Properties
| Property | Value |
|---|---|
| applicant_name | ORGANON LLC A SUB OF ORGANON AND CO |
| application_type | NDA |
| approval_date | 1995-04-28 |
Revenue by product
HYZAAR
| Period | Revenue |
|---|---|
| Q2 2026 | $50.0M* |
| Q1 2026 | $57.0M* |
| Q4 2025 | $53.0M* |
| Q3 2025 | $55.0M* |
| Q2 2025 | $56.0M* |
| Q1 2025 | $55.0M* |
| Q4 2024 | $57.0M* |
| Q3 2024 | $59.0M* |
| Q2 2024 | $60.0M* |
| Q1 2024 | $67.0M* |
| Q4 2023 | $56.0M* |
| Q3 2023 | $68.0M* |
| Q2 2023 | $71.0M* |
| Q1 2023 | $85.0M* |
| Q4 2022 | $67.0M* |
| Q3 2022 | $70.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| HYZAAR | HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM | 12.5MG;50MG | TABLET;ORAL |
| HYZAAR | HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM | 25MG;100MG | TABLET;ORAL |
| HYZAAR | HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM | 12.5MG;100MG | TABLET;ORAL |
3 products